Vitamin E and nonalcoholic fatty liver disease

Area of Science:

• Hepatology
• Nutritional Science
• Oxidative Stress Research

Background:

• Oxidative stress is a key factor in the progression of nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH).
• Reducing oxidative stress is a potential therapeutic target for NASH.
• Vitamin E, an antioxidant, has biological activities relevant to liver health.

Purpose of the Study:

• To review the role of oxidative stress in NASH.
• To discuss the biological activities of vitamin E.
• To evaluate the therapeutic efficacy of vitamin E in NASH patients.

Main Methods:

• Review of existing literature and clinical trial data.
• Analysis of studies investigating vitamin E in NASH treatment.
• Examination of evidence from trials like PIVENS and TONIC.

Main Results:

• Vitamin E therapy significantly improved steatosis, inflammation, and ballooning in adult NASH patients without diabetes or cirrhosis (PIVENS trial).
• Vitamin E showed significant NASH resolution in children, but sustained alanine aminotransferase reduction was not achieved (TONIC trial).

Conclusions:

• Vitamin E (RRR-α-tocopherol) is recommended for NASH adults with aggressive histology, excluding those with diabetes or cirrhosis.
• Evidence for vitamin E use in children with NASH requires further validation.
• Long-term safety data from randomized controlled trials are necessary to assess vitamin E's sustained use.